Drugs / BLU-924
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07629960 | Jun 2026 → Sep 2029 expected | colorectal neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Blueprint Medicines Corporation | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLU-924 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07629960 ↗ |
| Action | Inhibit | “a pan-KRAS inhibitor” NCT07629960 ↗ |
| Route | Oral | “BLU-924 oral tablet” NCT07629960 ↗ |
| Target | KRAS | “a pan-KRAS inhibitor” NCT07629960 ↗ |